<DOC>
	<DOCNO>NCT00605228</DOCNO>
	<brief_summary>Primary : - To demonstrate superiority Moviprep® versus Colopeg® gut cleanse prior colonoscopy . Secondary : - To assess safety Moviprep® versus Colopeg® . - To assess acceptability Moviprep® versus Colopeg® .</brief_summary>
	<brief_title>A Phase IV Study , Efficacy , Safety , Acceptability Moviprep® Versus Colopeg® Colonoscopy Preparation</brief_title>
	<detailed_description>Primary efficacy analysis perform ITT population . Secondary efficacy analysis perform ITT PP set . Results summarise treatment age ( overall , 18-35 , 36-49 , 50-74 75-85 year old ) provide individual data listing . Safety analysis perform safety set ( ITT population ) . Safety data patient expose summarised treatment age ( overall , 18-35 , 36-49 , 50-74 75-85 year old ) . Acceptability analysis perform ITT population . Acceptability data patient summarise treatment age ( overall , 18-35 , 36-49 , 50-74 75-85 year old ) .</detailed_description>
	<mesh_term>Gastrointestinal Diseases</mesh_term>
	<mesh_term>Digestive System Diseases</mesh_term>
	<criteria>1 . The patient 's write informed consent must obtain prior inclusion . 2 . Male female , outpatients 18 85 year old indication colonoscopy . 3 . Willing able complete entire procedure comply study instruction . 4 . Females childbearing potential must employ adequate method birth control . 1 . Age &lt; 18 &gt; 85 year old , 2 . Ileus , 3 . Suspected intestinal occlusion perforation , 4 . Toxic megacolon severe inflammation condition intestinal tract ( patient Crohn 's Disease Ulcerative Colitis include ) , 5 . Gastroparesis , 6 . Congestive heart failure NYHA III IV , 7 . Documented Carcinoma colic disease lead fragile mucosa , 8 . Documented severe renal insufficiency history 9 . Known hypersensitivity MoviPrep® , Colopeg® component ( PEG , ascorbic acid etc . ) , 10 . Known deficiency G6PD and/or phenylketonuria , 11 . Concurrent participation investigational drug/device study participation within 30 day study entry , 12 . Females pregnant , planning pregnancy . Females child bear potential use reliable method birth control , 13 . Clinically significant laboratory abnormality disease , opinion investigator , create risk patient , obscure effect study treatment interfere study result . 14 . Vulnerable patient ( protected law ) admit sanitary/social institution accord Art.L11216 French Public Health Code .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2008</verification_date>
</DOC>